VIDEO: Subgroup analysis backs adjuvant pembrolizumab after nephrectomy in RCC
Click Here to Manage Email Alerts
SAN FRANCISCO — In this video, Toni K. Choueiri, MD, gives a summary of a subgroup analysis of the KEYNOTE-564 study he presented at the annual ASCO Genitourinary Cancers Symposium.
Findings from the KEYNOTE-564 study demonstrated prolonged DFS with adjuvant pembrolizumab (Keytruda, Merck) among patients with renal cell carcinoma who were at increased risk for recurrence after nephrectomy, according to the abstract.
The researchers conducted an exploratory post-hoc analysis to determine the efficacy of the adjuvant treatment in UCLA Integrated Staging System (UISS) risk groups, as well as by disease stage.
“We found the majority of patients — over 70% — were in the UISS intermediate risk group, and adjuvant pembrolizumab actually prolonged the disease free survival and metastases-free survival compared [with] placebo all through [the] subgroup of UISS population,” Choueiri, Jerome and Nancy Kohlberg professor of medicine at Harvard Medical School and attending physician in solid tumor oncology, director of the Genitourinary Oncology Disease Center, and director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, said.
Reference:
- Choueiri TK, et al. Abstract 679. Presented at: ASCO Genitourinary Cancers Symposium; Feb. 16-18, 2022; San Francisco.
Collapse
Healio Interviews
Click Here to Manage Email Alerts